Catalio Capital Management

Tracked participation in 2 Atlas companies, with 1 explicitly attributed lead.

2portfolio companies

3round participations

1lead positions

$53Mled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Jul 2021Iambic TherapeuticsSeries A$53M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

LSLila SciencesScienceLila Sciences (lila.ai) is a privately held AI-for-science company building what it calls an “operating system for…$1.3Bvaluation$985MraisedRecent roundsSeries A (final close / total round close as disclosed) · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) (wholly owned subsidiary), Altitude Life Science Ventures +7Series A (milestone close) · Sep 2025$235M · led by Braidwell, Collective Global +1Lila Sciences$1.3BOct 2025 → Oct 20251 roundParticipant—

ITIambic TherapeuticsScienceIambic Therapeutics develops AI-native small-molecule medicines by combining (1) physics-informed neural models for…$8.4Mvaluation$258.5MraisedRecent roundsOversubscribed financing (round size disclosed as “over $100 million”) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +16Series A · Jul 2021$53M · led by Catalio Capital Management, CoatueSeries Seed · Apr 2020$2.5M · Freeflow Ventures, Nexus Venture PartnersIambic Therapeutics—Jul 2021 → Jul 20212 rounds1 led—

DateCompanyRoundRaisedValuationRoleEvidence

Oct 10, 2025LSLila SciencesScienceLila Sciences (lila.ai) is a privately held AI-for-science company building what it calls an “operating system for…$1.3Bvaluation$985MraisedRecent roundsSeries A (final close / total round close as disclosed) · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) (wholly owned subsidiary), Altitude Life Science Ventures +7Series A (milestone close) · Sep 2025$235M · led by Braidwell, Collective Global +1Lila SciencesSeries A (final close / total round close as disclosed)$350M$1.3BParticipant

Source ↗+1 ↗

Jul 14, 2021ITIambic TherapeuticsScienceIambic Therapeutics develops AI-native small-molecule medicines by combining (1) physics-informed neural models for…$8.4Mvaluation$258.5MraisedRecent roundsOversubscribed financing (round size disclosed as “over $100 million”) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +16Series A · Jul 2021$53M · led by Catalio Capital Management, CoatueSeries Seed · Apr 2020$2.5M · Freeflow Ventures, Nexus Venture PartnersIambic TherapeuticsSeries A$53M—Lead

Source ↗

UndatedITIambic TherapeuticsScienceIambic Therapeutics develops AI-native small-molecule medicines by combining (1) physics-informed neural models for…$8.4Mvaluation$258.5MraisedRecent roundsOversubscribed financing (round size disclosed as “over $100 million”) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +16Series A · Jul 2021$53M · led by Catalio Capital Management, CoatueSeries Seed · Apr 2020$2.5M · Freeflow Ventures, Nexus Venture PartnersIambic TherapeuticsSeries B$100M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗+1 ↗

Source ↗